Dr. Reddy’s Laboratories launches Pregabalin Capsules in US Market
30th Jul 2019

Dr. Reddy’s Laboratories has launched Pregabalin Capsules a therapeutic equivalent generic version of Lyrica (pregabalin) capsules approved by the U.S. Food and Drug Administration (USFDA). The Lyrica (pregabalin) Capsules brand had U.S. sales of approximately $5,462 million MAT for the most recent twelve months ending in May 2019 according to IQVIA Health.

The company’s Pregabalin Capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90. This is also a controlled substance schedule V product. Lyrica is a trademark of C.P. Pharmaceuticals International C.V.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.